Windle R, Bell P R, Shaw D
Br J Surg. 1987 Jul;74(7):569-72. doi: 10.1002/bjs.1800740707.
Following curative surgery for colorectal cancer 141 patients were randomized to receive a 6 month course of 5-fluorouracil (5FU) with or without postoperative levamisole or supportive treatment only. The patients have been followed up for a minimum of 5 years and 52 per cent of patients in the control group, 44 per cent of the 5FU group and 32 per cent of the 5FU/levamisole group have died of tumour recurrence. This represents a significant survival advantage in the patients receiving levamisole, even when other patient and tumour factors are allowed for.
在接受结直肠癌根治性手术后，141例患者被随机分为三组，分别接受为期6个月的5-氟尿嘧啶（5FU）治疗，其中一组同时加用术后左旋咪唑，另一组仅接受支持治疗。这些患者至少随访了5年，对照组中有52%的患者、5FU组中有44%的患者以及5FU/左旋咪唑组中有32%的患者死于肿瘤复发。即使考虑了其他患者和肿瘤因素，接受左旋咪唑治疗的患者仍具有显著的生存优势。
